|
Oct 9
|
Lantern Pharma Inc (LTRN) Q2 2024 Earnings Call Highlights: Promising Clinical Trials and ...
|
|
May 14
|
LTRN: Expanding Horizons into Asia
|
|
May 9
|
Lantern Pharma Reports First Quarter 2024 Financial Results and Business Highlights
|
|
May 6
|
Lantern Pharma and Oregon partner to develop cancer treatment
|
|
May 6
|
Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism
|
|
May 2
|
Lantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ET
|
|
Apr 24
|
Lantern Pharma Launches "Webinar Wednesdays" Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development
|
|
Apr 22
|
Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan
|
|
Mar 19
|
Lantern Pharma Inc. (NASDAQ:LTRN) Q4 2023 Earnings Call Transcript
|
|
Mar 19
|
LTRN: 2023 Results
|
|
Mar 18
|
Lantern Pharma Inc Reports Progress and Financials for FY 2023
|
|
Mar 18
|
Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights
|
|
Mar 15
|
Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284
|
|
Mar 11
|
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2023 Operating & Financial Results on March 18th, 2024 at 4:30 p.m. ET
|
|
Mar 7
|
11 Best Artificial Intelligence Stocks Under $20 According To Hedge Funds
|
|
Mar 5
|
Lantern To Participate in H.C Wainwright & Co.’s (HCW) 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference
|
|
Mar 4
|
Lantern Pharma's A.I. Platform, RADR®, Surpasses 60 Billion Data Points – Anticipates Reaching 100 Billion Data Points in 2024, Paving the Way for Enhanced Cancer Therapy Innovations and Expedited Development Timelines
|
|
Feb 15
|
Lantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor Cancers
|
|
Jan 17
|
Starlight Therapeutics, a Subsidiary of Lantern Pharma Focused on CNS & Brain Cancers, Announces Dr. Marc Chamberlain as Chief Medical Officer
|
|
Nov 30
|
FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in High-Grade B-cell Lymphomas (HGBL)
|